SCHEMBL20938429

SCHEMBL20938429

Nc1ncnc2c1c(C(F)(F)F)cn2[C@@H]1O[C@H](CO)C[C@H]1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 3/20 0.50
▸ WDR77 Q9BQA1 1/20 0.50
▸ METTL3 Q86U44 2/20 0.45
▸ ADK P55263 7/20 0.44
▸ DOT1L Q8TEK3 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ GALR3 O60755 1/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ HTR2B P41595 5/20 0.44
▸ SIGMAR1 Q99720 4/20 0.44
▸ OPRK1 P41145 2/20 0.44
▸ ADRA2C P18825 1/20 0.44
▸ HTR6 P50406 1/20 0.44
▸ TMEM97 Q5BJF2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14134801 0.86 PRMT5 (0.48) PRMT5WDR77METTL3ADKDOT1L
SCHEMBL22912603 0.86 PRMT5 (0.48) PRMT5WDR77METTL3ADKDOT1L
SCHEMBL20938258 0.84 ADK (0.49) METTL3ADK
SCHEMBL13068771 0.84 ADK (0.61) PRMT5WDR77ADKDOT1LNPC1
SCHEMBL20419136 0.84 ADK (0.59) METTL3ADK
SCHEMBL20938262 0.84 ADK (0.59) METTL3ADK
SCHEMBL20419234 0.84 ADK (0.59) METTL3ADK
SCHEMBL3768787 0.84 ADK (0.61) PRMT5WDR77ADKDOT1LNPC1
SCHEMBL20938333 0.84 ADK (0.46) PRMT5METTL3ADKDOT1LNPC1
SCHEMBL20419264 0.84 ADK (0.61) PRMT5WDR77ADKDOT1LNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections UNIVERSITEIT GENT (BE) 2021-07-27 — — US disclosed
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2021-01-28 — — US disclosed
WO-2019076633-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections PNP, NUDT1, SAMHD1 PRMT5 716/4885WDR77 906/4885METTL3 274/4885
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS PNP, NUDT1, SAMHD1 PRMT5 716/4885WDR77 906/4885METTL3 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback